Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension
| Autor: | Victor Z. C. Ye, K. A. Duggan, Jim L.C. Yong, George Hodge |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Pyridines Thiazepines Vasoactive intestinal peptide Rats Inbred WKY Enalapril Fibrosis Internal medicine Medicine Animals Protease Inhibitors Pharmacology biology business.industry Myocardium Angiotensin-converting enzyme medicine.disease Rats Blood pressure Endocrinology Circulatory system Hypertension biology.protein Myocardial fibrosis Omapatrilat business hormones hormone substitutes and hormone antagonists medicine.drug Peptide Hydrolases Vasoactive Intestinal Peptide |
| Zdroj: | European journal of pharmacology. 485(1-3) |
| ISSN: | 0014-2999 |
| Popis: | We have shown previously that the concentration of Vasoactive Intestinal Peptide (VIP) in the heart is inversely correlated with the degree of fibrosis in a number of experimental models of early myocardial fibrosis. Vasopeptidase inhibition and angiotensin converting enzyme inhibition both decrease myocardial fibrosis. In this study, we sought to determine whether this myocardial protective effect might reflect increased VIP concentrations in the heart. We compared the effects of 4 weeks treatment of the vasopeptidase inhibitor omapatrilat and the angiotensin converting enzyme inhibitor enalapril on the degree of fibrosis and the concentration of VIP in the heart in salt sensitive hypertension induced by treatment with L-nitro-omega-methylarginine (L-NAME). Systolic blood pressure decreased in both treatment groups compared with control (omapatrilat P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect